Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial ofd -Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment
| Autor: | Imad Khamis, Karl Goodkin, Rebeca Molina, Paul Shapshak, Peter N. R. Heseltine, Frances L. Wilkie, Benedetto Vitiello, Wenli Zheng, William D. Lyman, Deshratn Asthana, J. Hampton Atkinson |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Serum medicine.medical_specialty AIDS Dementia Complex Adolescent Placebo-controlled study CSF CCR5 receptor antagonist Placebo Gastroenterology Monocytes Leukocyte Count Plasma Cellular and Molecular Neuroscience chemistry.chemical_compound Cognition Virology Internal medicine medicine Humans Cerebrospinal Fluid biology business.industry HIV Reproducibility of Results Peptide T Viral Load biology.organism_classification Clinical trial Treatment Outcome Neurology chemistry Immunology Lentivirus HIV-1 Female Neurology (clinical) Viral disease DAPTA business Viral load |
| Zdroj: | Journal of Neurovirology. 12:178-189 |
| ISSN: | 1538-2443 1355-0284 |
| DOI: | 10.1080/13550280600827344 |
| Popis: | D-Ala1-peptide T-amide (DAPTA) has shown neuroprotection in vitro against gp120-induced loss of dendritic arborization and is promulgated as a CCR5 antagonist. A multisite, randomized, double-blind clinical trial of DAPTA versus placebo prior to combination antiretroviral therapy conducted with human immunodeficiency virus (HIV)-1 seropositive participants having cognitive impairment showed no overall cognitive effect, though subgroups with greater impairment and CD4 cell counts of 201 to 500 cells/mm3 at baseline showed significant improvement. The objective of this study was to examine whether intranasal administration of DAPTA at a dose of 2 mg three times per day (tid) was associated with a reduction of cerebrospinal fluid (CSF) and peripheral (plasma and serum) viral load among a subgroup of participants completing 6 months of treatment. Baseline and 6-month CSF (n = 92) and peripheral (plasma n = 33; serum n = 24) viral load were measured by the Roche Ultrasensitive assay, version 1.5, with reflexive use of the AMPLICOR assay and preservation of the blind. A DAPTA treatment indicator variable was tested using generalized linear models on change in viral load. Peripheral load (combined plasma and serum) was significantly reduced in the DAPTA-treated group. No group differences in CSF viral load were found. This retrospective study on a limited subgroup of the original trial sample indicated that DAPTA treatment may reduce peripheral viral load without concomitant CSF effects. Future studies should be undertaken to confirm the existence of this result and the CSF-periphery dissociation observed with respect to HIV-1-associated cognitive-motor impairment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink